{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:04:36Z","timestamp":1777950276279,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00932"],"award-info":[{"award-number":["PI19\/00932"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["FI20\/00090"],"award-info":[{"award-number":["FI20\/00090"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115058","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T05:02:22Z","timestamp":1687928542000},"page":"115058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers"],"prefix":"10.1016","volume":"165","author":[{"given":"Gonzalo","family":"Villapalos-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Soria-Chacartegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Navares-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Matas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Mej\u00eda-Abril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Casaj\u00fas-Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Campod\u00f3nico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Mart\u00edn-V\u00edlchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Candau-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Aldama-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115058_bib1","unstructured":"Food and Drug Administration (FDA). Xarelto drug label [Internet]. [cited 2023 Mar 13]. Available from: \u3008https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf\u3009."},{"key":"10.1016\/j.biopha.2023.115058_bib2","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS). Xarelto drug label [Internet]. [cited 2023 Mar 13]. Available from: \u3008https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/08472018\/FT_08472018.html\u3009."},{"issue":"5","key":"10.1016\/j.biopha.2023.115058_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/dmd.108.025551","article-title":"In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans","volume":"37","author":"Lang","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.biopha.2023.115058_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/FJC.0000000000000870","article-title":"Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio","volume":"76","author":"Bernier","year":"2020","journal-title":"J. Cardiovasc Pharm."},{"key":"10.1016\/j.biopha.2023.115058_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15884","article-title":"The myths behind DOAC measurement: Analyses of prescribing information from different regulatory bodies and a call for harmonization","author":"Gosselin","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2023.115058_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.817826","article-title":"Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study","volume":"9","author":"Meihandoest","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.biopha.2023.115058_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/jpm11010037","article-title":"Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review","volume":"11","author":"Raymond","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.biopha.2023.115058_bib8","doi-asserted-by":"crossref","unstructured":"Gosselin R.C., Douxfils J. Measuring Direct Oral Anticoagulants. In: Favaloro E.J., Lippi G., editors. Hemostasis and Thrombosis [Internet]. New York, NY: Springer New York; 2017 [cited 2022 Oct 19]. p. 217\u2013225. (Methods in Molecular Biology; vol. 1646). Available from: \u3008http:\/\/link.springer.com\/10.1007\/978\u20131-4939\u20137196-1_18\u3009.","DOI":"10.1007\/978-1-4939-7196-1_18"},{"issue":"3","key":"10.1016\/j.biopha.2023.115058_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2023.115058_bib10","doi-asserted-by":"crossref","unstructured":"Ing Lorenzini K., Daali Y., Fontana P., Desmeules J., Samer C. ,Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol [Internet]. 2016 Dec 19 [cited 2022 Sep 19];7. Available from: \u3008http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2016.00494\/full\u3009.","DOI":"10.3389\/fphar.2016.00494"},{"issue":"7","key":"10.1016\/j.biopha.2023.115058_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/17425255.2017.1338274","article-title":"The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)","volume":"13","author":"O\u2019connor","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115058_bib12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13577","article-title":"Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB 1 genetic polymorphisms and interaction with clarithromycin","volume":"15","author":"Gouin\u2010Thibault","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2023.115058_bib13","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki. Law Med Health Care. 1991;19(3\u20134):264\u2013265.","DOI":"10.1111\/j.1748-720X.1991.tb01824.x"},{"key":"10.1016\/j.biopha.2023.115058_bib14","unstructured":"European Medicines Agency (EMA), Guideline on the investigation ofbioequivalence. CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr. 2010."},{"issue":"5","key":"10.1016\/j.biopha.2023.115058_bib15","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/cpt.1322","article-title":"Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research","volume":"105","author":"Huddart","year":"2019","journal-title":"Clin. Pharm. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2023.115058_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.medcli.2016.06.012","article-title":"Evaluaci\u00f3n de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Espa\u00f1ol de Farmacovigilancia","volume":"147","author":"Aguirre","year":"2016","journal-title":"Med Cl\u00ednica"},{"issue":"6","key":"10.1016\/j.biopha.2023.115058_bib17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin. Pharm. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115058_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2023.115058_bib19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2023.115058_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharm. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2023.115058_bib21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin\u2010Associated Musculoskeletal Symptoms","volume":"111","author":"Cooper\u2010DeHoff","year":"2022","journal-title":"Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2023.115058_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin. Pharm. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2023.115058_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2023.115058_bib24","doi-asserted-by":"crossref","unstructured":"Ilett K.F., Kadlubar F.F., Minchin R.F., 1998, International Meeting on the Arylamine N-Acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk. Drug Metab Dispos Biol Fate Chem. 1999 Sep;27(9):957\u20139.","DOI":"10.1016\/S0090-9556(24)15009-X"},{"key":"10.1016\/j.biopha.2023.115058_bib25","doi-asserted-by":"crossref","unstructured":"Hein D.W., Grant D.M., Sim E. Update on consensus arylamine N-acetyltransferase gene nomenclature: Pharmacogenetics. 2000 Jun;10(4):291\u20132.","DOI":"10.1097\/00008571-200006000-00002"},{"issue":"11","key":"10.1016\/j.biopha.2023.115058_bib26","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2217\/14622416.9.11.1673","article-title":"Update on the pharmacogenetics of NATs: structural considerations","volume":"9","author":"Stanley","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.biopha.2023.115058_bib27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2217\/pgs.13.94","article-title":"OCT1 genetic variants influence the pharmacokinetics of morphine in children","volume":"14","author":"Fukuda","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2023.115058_bib28","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.2147\/DDDT.S80066","article-title":"A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles","author":"Chung","year":"2015","journal-title":"Drug Des. Devel Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.115058_bib29","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/ijc.29654","article-title":"Clinical validity of a DPYD -based pharmacogenetic test to predict severe toxicity to fluoropyrimidines: DPYD Polymorphisms and Fluoropyrimidines Toxicity","volume":"137","author":"Toffoli","year":"2015","journal-title":"Int J. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2023.115058_bib30","doi-asserted-by":"crossref","first-page":"10393","DOI":"10.1007\/s13277-016-4908-2","article-title":"DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia","volume":"37","author":"Zhao","year":"2016","journal-title":"Tumor Biol."},{"issue":"13","key":"10.1016\/j.biopha.2023.115058_bib31","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/QAD.0b013e32830719aa","article-title":"First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America","volume":"22","author":"Young","year":"2008","journal-title":"AIDS"},{"issue":"17","key":"10.1016\/j.biopha.2023.115058_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10173772","article-title":"PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics","volume":"10","author":"Zubiaur","year":"2021","journal-title":"J. Clin. Med"},{"issue":"8","key":"10.1016\/j.biopha.2023.115058_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FPC.0000000000000062","article-title":"PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2","volume":"24","author":"McDonagh","year":"2014","journal-title":"Pharm. Genom."},{"issue":"3","key":"10.1016\/j.biopha.2023.115058_bib34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin. Pharm. Ther."},{"issue":"3Part-I","key":"10.1016\/j.biopha.2023.115058_bib35","first-page":"589","article-title":"Rasagiline Pharmacokinetics in CYP1A2 Variant Healthy Smokers & Non-smokers in Different Doses","volume":"38","author":"Bilal","year":"2022","journal-title":"Pak. J. Med Sci."},{"issue":"113747","key":"10.1016\/j.biopha.2023.115058_bib36","article-title":"Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam","volume":"155","author":"Zubiaur","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.115058_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects: Drug interactions with rivaroxaban","volume":"76","author":"Mueck","year":"2013","journal-title":"Br. J. Clin. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.115058_bib38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.biopha.2023.115058_bib39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/dmd.108.025551","article-title":"In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans","volume":"37","author":"Lang","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.biopha.2023.115058_bib40","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab. Dispos."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222300848X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222300848X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:55:54Z","timestamp":1777877754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222300848X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":40,"alternative-id":["S075333222300848X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115058","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115058"}}